Denali Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
DNLI$20.33+1.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share amounts)
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $174,960 | $127,106 |
| Short-term marketable securities | 657,371 | 907,405 |
| Prepaid expenses and other current assets | 32,105 | 29,626 |
| Total current assets | 864,436 | 1,064,137 |
| Long-term marketable securities | 359,373 | — |
| Property and equipment, net | 55,236 | 45,589 |
| Finance lease right-of-use asset | 47,533 | — |
| Operating lease right-of-use asset | 22,861 | 26,048 |
| Other non-current assets | 24,741 | 18,143 |
| Total assets | $1,374,180 | $1,153,917 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $11,137 | $9,483 |
| Accrued expenses and other current liabilities | 91,071 | 68,499 |
| Total current liabilities | 102,208 | 77,982 |
| Operating lease liability, less current portion | 36,673 | 44,981 |
| Finance lease liability, less current portion | 5,615 | — |
| Total liabilities | 144,496 | 122,963 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity: | ||
| Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.01 par value; 400,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 144,220,986 and 138,385,498 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 1,768 | 1,711 |
| Additional paid-in capital | 2,764,880 | 2,144,811 |
| Accumulated other comprehensive income | 2,020 | 643 |
| Accumulated deficit | (1,538,984) | (1,116,211) |
| Total stockholders’ equity | 1,229,684 | 1,030,954 |
| Total liabilities and stockholders’ equity | $1,374,180 | $1,153,917 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.